SUMMARY REPORTS

Advances in autosomal dominant polycystic kidney disease: improving patient care to slow disease progression – Organised by SANOFI GENZYME

When delays could lead to ESKD. Identifying and managing primary hyperoxaluria in clinical practice – Organised by ALNYLAM PHARMACEUTICALS

SGLT2 inhibition in CKD: Our chance to make a difference – Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca

K+: Recurrence, Restriction and Fluctuation. Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca